1Donohue JH,Stewart AK ,Menck HR, et al. The national cancer date base report on carcinoma of the gallbladder, 1989-1995 [J]. Cancer, 1998,83 ( 12 ) : 2618-2628.
2Heller J, Schepke M, Neef M, et al. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension[J]. Hepatol, 2002,37 (6) : 767-772.
3Egeblad M,Werb Z. New functions for the matrix metaloproteinase in cancer progression[J]. Nature Rev Cancer,2002,2(3) : 164-174.
4Shirabe K, Shmada M, Kajiyama K, et al. Expression of matrix metaUoproteinase-9 in surgically resected intrahepatic cholangiocarcinoma[J]. Surgery, 1999,126 ( 5 ) : 842-846.
5Yao J,Xiong S,Klos K,et al. Multiple signaling pathways involved in activation of matrix metalloproteinase (MMP-9) by heregulin betal in human breast cancer cells[J]. Oncogene, 2001,20: 8066-8069.
6Kim TD, Song KS, Li G, et al. Activity and expression of urokinasetype plasminogen activator and matrix metaUoproteinases in human colorectal cancer[J]. BMC Cancer,2006,6:211.
7Zheng H,Takahshi H,Murai Y,et al. Expressions of MMP-2,MMP-9 and VEGF are closely linked to growth,invasion,metastasis and angiogenesis of gastric careinoma[J]. Anticancer Res, 2006, 26(5A): 3579-3581.
8Sun WH,Sun YL,Fang RN,et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis[J]. Jpn J Clin Oneol, 2005,35 (12):707-709.
9Steeg PS,Bevilacqua G,Kopper L,et al. Evidence for a novel gene associated with low tumor metastatic potential[J]. J Nail Cancer, 1998, 80( 1 ) :200-202.
10Chow NH, LiuHS, Chan SH. The role of nm23-H1 in the progression of transitional cellbladder cancer[J]. Clin Cancer Res,2000, 6(9) : 3595-3599.
